Anzeige
Mehr »
Login
Sonntag, 03.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Technischer Ausbruch: Diese Kupferaktie ist in den letzten 52 Wochen um 300 % gestiegen! Der Durchbruch läuft!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P5N7 | ISIN: FI4000330972 | Ticker-Symbol: 4YL
Frankfurt
01.11.24
08:20 Uhr
1,326 Euro
-0,038
-2,79 %
Branche
Nanotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
NANOFORM FINLAND OYJ Chart 1 Jahr
5-Tage-Chart
NANOFORM FINLAND OYJ 5-Tage-Chart
RealtimeGeldBriefZeit
1,2841,32002.11.

Aktuelle News zur NANOFORM FINLAND Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
25.10.Disclosure as attachment of the Nanoform 2022 Report of the Board of Directors and Financial Statements which were previously linked to a Company Release2
22.10.Share subscriptions based on Nanoform Finland Plc's stock options 2/20191
05.09.Nanoform and Celanese Expand Collaboration into Long-Acting Biologics Delivery Through Small Implants5
29.08.Nanoform Q2 report: All business targets for 2024 on track1
16.08.Invitation to Nanoform's Q2 2024 Report Presentation1
15.08.Nanoform Collaborates with Takeda on Plasma-derived Therapy Development14
15.08.NANOFORM COLLABORATES WITH TAKEDA ON THEIR PLASMA-DERIVED THERAPY DEVELOPMENT748HELSINKI, Aug. 15, 2024 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that it is to enter into a pre-clinical development...
► Artikel lesen
14.06.Nanoform Finland Plc - Manager's Transactions - Miguel Calado1
14.06.Nanoform Finland Plc - Manager's Transactions - Albert Hæggström3
14.06.Share subscriptions based on the resolution by Nanoform Finland Plc's Annual General Meeting 2024 on remuneration of the Board of Directors1
14.06.Nanoform Finland Plc - Manager's Transactions - Mads Laustsen1
14.06.Nanoform Finland Plc - Manager's Transactions - Jeanne Thoma1
30.05.Nanoform's biologics technology showcased by large pharma at drug delivery conference; Nanoenzalutamide and nanoapalutamide partnering discussions progress as planned495HELSINKI, May 30, 2024 /PRNewswire/ -- Manufacturing of GMP material in Project Nanoenzalutamide commenced. EU/US pivotal studies are planned to start in 4Q24, with the read-out in 1Q25....
► Artikel lesen
29.05.NANOFORM: Disclosure of Major Holdings under Law 163/20241
16.05.Invitation to Nanoform's Q1 2024 Report Presentation2
09.04.Nanoform and PlusVitech partner to repurpose aprepitant as a treatment for lung cancer734Nanoform Finland Plc April 9, 2024 09.00 EEST / 08.00 CEST HELSINKI, April 9, 2024 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company...
► Artikel lesen
15.02.Inside information made public: Nanoform Wins R&D Grant of EUR 4.3M for Research Into Nanoparticle Enabled Formulations for Next Generation Medicines618THIS PRESS RELEASE CONTAINS INFORMATION THAT NANOFORM IS OBLIGED TO MAKE PUBLIC PURSUANT TO THE EU MARKET ABUSE REGULATION. THE INFORMATION WAS SENT FOR PUBLICATION THROUGH THE AGENCY OF...
► Artikel lesen
26.01.Inside information made public: Nanoform Announces Important Milestone with Promising Clinical Results for Patient-Centric Nanotechnology-Enhanced Enzalutamide676THIS PRESS RELEASE CONTAINS INFORMATION THAT NANOFORM IS OBLIGED TO MAKE PUBLIC PURSUANT TO THE EU MARKET ABUSE REGULATION. THE INFORMATION WAS SENT FOR PUBLICATION THROUGH THE AGENCY OF...
► Artikel lesen
05.01.Nanoform Commenced Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide888HELSINKI, Jan. 5, 2024 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), the medicine performance enhancing company, today announced it had completed the First Subject First Visit (FSFV)...
► Artikel lesen
19 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1